Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have moved closer to developing a reliable vaccine for a mosquito-borne virus that causes fever, rash and joint and muscle pain in infected patients in Europe, Asia and Africa.

University of Florida (UF) researchers have identified potential protection against impairment following a stroke in the form of selexipag, a Food & Drug Administration-approved (FDA) drug.

After the Healthcare Leadership Council (HLC) hosted a Capitol Hill bringing addressing the need for innovation in the nation’s healthcare workforce, the concerns now remain on how the industry is supposed to modernize during a time of varying factors.

Newly released results from an international Phase 3 clinical trial show Xultophy 100/3.6, a new treatment for diabetes developed by Novo Nordisk Inc. is more effective than traditional insulin alone and eliminates some insulin side effects.

Masimo said in a release that results of a study that compared the Massimo Patient State Index (PSi) versus the Next Generation SedLine PSi version were presented at Euroanaesthesia 2017 in Geneva, Switzerland.

In a move designed to boost efficiency and more closely focus on the patient experience, Mapi Group, a contract research organization for the pharmaceutical industry based in Lyon, France, has restructured operations to bring three divisions under one umbrella.

SCI Solutions said in a release it has upgraded its health care scheduling solution, Schedule Maximizer. The cloud-based enterprise health care scheduling platform provides a seamless system for health providers.

Eli Lilly and Co. said three of its Phase 3 studies of galcanezumab, an investigational treatment to prevent episodic and chronic migraines, have found that galcanezumab significantly reduces the amount of migraine headache days experienced by sufferers.

LLS Community, a free online network started by The Leukemia & Lymphoma Society (LLS) that offers support and education to blood cancer patients and their caregivers, said in a release it will partner Medivizor, an Israeli technology startup, to provide cutting-edge health information to the network.

Jeremy Wynes, a Republican candidate U.S. representative in Illinois' 10th Congressional District, took to social media after the New York Times (NYT) estimated that 45 counties and up to 35,000 people would have no Affordable Care Act (ACA) carriers in 2018.

Olaparib, marketed by AstraZeneca under the trade name Lynparza, a drug that blocks breast cancer cells’ ability to self-repair, has completed six years of study proving it bests traditional chemotherapy, according to a June 4 release from Penn Medicine in Philadelphia.

U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb recently said digital health technology will be a priority focus during his tenure.

Anthem, a health insurance provider that has stood by the Affordable Care Act, also known as Obamacare, longer than many other insurers, said it is pulling out of the Wisconsin and Indiana marketplaces due to "volatile" markets.

An amendment to an international Phase 3 clinical trial for prostate cancer drug Xtandi (enzalutamide) will cut the sample size by 120 subjects and provide results later this year, nearly two years ahead of schedule.

Breast cancer patients who receive even a single chemotherapy treatment can experience a major impact on their walking gait and balance, boosting their fall risk, according to a recent study conducted by the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James).

Clues are emerging about the brain science behind the social difficulties of people with autism spectrum disorder (ASD) thanks to a group of investigators at the Martinos Center for Biomedical Imaging at Boston’s Massachusetts General Hospital.

AbbVie said new information about Imbruvica (ibrutinib) shows that it is stronger than chlorambucil in fighting chronic lymphocytic leukemia in certain patients.

A vaccine for Group B Streptococcus, a potentially deadly virus that can cause brain damage in up to half of those affected, is undergoing a Phase 1 clinical trial by Pfizer Inc.

Results of a preliminary study of an antiplatelet drug based on a snake venom protein could pave the way for drugs that have fewer bleeding complications.

A drug formerly meant for cancer treatment may be better used to treat muscular dystrophy, according to researchers from the National Institutes of Health (NIH) and the University of Nevada, Reno School of Medicine.